211 related articles for article (PubMed ID: 30720096)
1. Integrative analysis of cancer driver genes in prostate adenocarcinoma.
Zhao X; Lei Y; Li G; Cheng Y; Yang H; Xie L; Long H; Jiang R
Mol Med Rep; 2019 Apr; 19(4):2707-2715. PubMed ID: 30720096
[TBL] [Abstract][Full Text] [Related]
2. The Integrated Analyses of Driver Genes Identify Key Biomarkers in Thyroid Cancer.
Xu Q; Song A; Xie Q
Technol Cancer Res Treat; 2020; 19():1533033820940440. PubMed ID: 32812852
[TBL] [Abstract][Full Text] [Related]
3. Integrated characterisation of cancer genes identifies key molecular biomarkers in stomach adenocarcinoma.
Wang H; Shen L; Li Y; Lv J
J Clin Pathol; 2020 Sep; 73(9):579-586. PubMed ID: 32034058
[TBL] [Abstract][Full Text] [Related]
4. Identification of Prognostic Biomarkers Associated with Cancer Stem Cell Features in Prostate Adenocarcinoma.
Zhang D; Zhang M; Zhang Q; Zhao Z; Nie Y
Med Sci Monit; 2020 Jul; 26():e924543. PubMed ID: 32735556
[TBL] [Abstract][Full Text] [Related]
5. Immune infiltration phenotypes of prostate adenocarcinoma and their clinical implications.
Ma Z; Cheng X; Yue T; Shangguan X; Xin Z; Zhang W; Pan J; Wang Q; Xue W
Cancer Med; 2021 Aug; 10(15):5358-5374. PubMed ID: 34128342
[TBL] [Abstract][Full Text] [Related]
6. Bioinformatics Analysis of GFAP as a Potential Key Regulator in Different Immune Phenotypes of Prostate Cancer.
Yao W; Li X; Jia Z; Gu C; Jin Z; Wang J; Yuan B; Yang J
Biomed Res Int; 2021; 2021():1466255. PubMed ID: 34222466
[TBL] [Abstract][Full Text] [Related]
7. The Integrative Method Based on the Module-Network for Identifying Driver Genes in Cancer Subtypes.
Lu X; Li X; Liu P; Qian X; Miao Q; Peng S
Molecules; 2018 Jan; 23(2):. PubMed ID: 29364829
[TBL] [Abstract][Full Text] [Related]
8. Identification of 10 differently expressed lncRNAs as prognostic biomarkers for prostate adenocarcinoma.
Wu ZY; Wang SG; Li Q; Zhao QS; Shao MM
Math Biosci Eng; 2019 Dec; 17(3):2037-2047. PubMed ID: 32233522
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value and potential function of splicing events in prostate adenocarcinoma.
Huang ZG; He RQ; Mo ZN
Int J Oncol; 2018 Dec; 53(6):2473-2487. PubMed ID: 30221674
[TBL] [Abstract][Full Text] [Related]
10. Tumor-antigens and immune landscapes identification for prostate adenocarcinoma mRNA vaccine.
Zheng X; Xu H; Yi X; Zhang T; Wei Q; Li H; Ai J
Mol Cancer; 2021 Dec; 20(1):160. PubMed ID: 34872584
[TBL] [Abstract][Full Text] [Related]
11. Gleason Score-related MT1L as biomarker for prognosis in prostate adenocarcinoma and contribute to tumor progression in vitro.
Liu L; Li Y; Tang S; Yang B; Zhang Q; Xiao R; Hou X; Liu C; Ma L
Int J Biol Markers; 2023 Jun; 38(2):114-123. PubMed ID: 37192745
[TBL] [Abstract][Full Text] [Related]
12. Interaction network analysis of YBX1 for identification of therapeutic targets in adenocarcinomas.
Murugesan SN; Yadav BS; Maurya PK; Chaudhary A; Singh S; Mani A
J Biosci; 2019 Jun; 44(2):. PubMed ID: 31180040
[TBL] [Abstract][Full Text] [Related]
13. Depiction of tumor stemlike features and underlying relationships with hazard immune infiltrations based on large prostate cancer cohorts.
Zhang C; Chen T; Li Z; Liu A; Xu Y; Gao Y; Xu D
Brief Bioinform; 2021 May; 22(3):. PubMed ID: 32856039
[TBL] [Abstract][Full Text] [Related]
14. An integrated analysis of cancer genes in clear cell renal cell carcinoma.
Li J; Guo L; Ai Z
Future Oncol; 2017 Apr; 13(8):715-725. PubMed ID: 28266251
[TBL] [Abstract][Full Text] [Related]
15. Spatial Intratumor Genomic Heterogeneity within Localized Prostate Cancer Revealed by Single-nucleus Sequencing.
Su F; Zhang W; Zhang D; Zhang Y; Pang C; Huang Y; Wang M; Cui L; He L; Zhang J; Zou L; Zhang J; Li W; Li L; Shao J; Ma J; Xiao F; Liu M
Eur Urol; 2018 Nov; 74(5):551-559. PubMed ID: 29941308
[TBL] [Abstract][Full Text] [Related]
16. In Silico Analysis of Gene Expression Change Associated with Copy Number of Enhancers in Pancreatic Adenocarcinoma.
Kumar R; Patiyal S; Kumar V; Nagpal G; Raghava GPS
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31336658
[TBL] [Abstract][Full Text] [Related]
17. Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations.
Böttcher R; Kweldam CF; Livingstone J; Lalonde E; Yamaguchi TN; Huang V; Yousif F; Fraser M; Bristow RG; van der Kwast T; Boutros PC; Jenster G; van Leenders GJLH
BMC Cancer; 2018 Jan; 18(1):8. PubMed ID: 29295717
[TBL] [Abstract][Full Text] [Related]
18. Nur77 Serves as a Potential Prognostic Biomarker That Correlates with Immune Infiltration and May Act as a Good Target for Prostate adenocarcinoma.
Hu QY; Liu J; Zhang XK; Yang WT; Tao YT; Chen C; Qian YH; Tang JS; Yao XS; Xu YH; Wang JH
Molecules; 2023 Jan; 28(3):. PubMed ID: 36770929
[TBL] [Abstract][Full Text] [Related]
19. Identification of Bone Metastatic and Prognostic Alternative Splicing Signatures in Prostate Adenocarcinoma.
Zhu J; Zhang J; Hu P; Fan M; Song D; Yin H; Yan P; Xian S; Li Z; Guo J; Long C; Xu R; Huang R; Meng T; Zhang J; Huang Z
Biochem Genet; 2023 Dec; 61(6):2242-2259. PubMed ID: 37010714
[TBL] [Abstract][Full Text] [Related]
20. Zinc finger C3H1 domain-containing protein (ZFC3H1) evaluates the prognosis and treatment of prostate adenocarcinoma (PRAD): A study based on TCGA data.
Huang H; Xu H; Li P; Ye X; Chen W; Chen W; Huang X
Bioengineered; 2021 Dec; 12(1):5504-5515. PubMed ID: 34514952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]